NEW YORK (GenomeWeb News) – Paul MacLeman, CEO of Australian firm Genetic Technologies, and other members of the firm's board and executive team resigned Tuesday following the firm's annual general meeting.

The resignations came after Chairman Mel Bridges and Director Huw Jones were not re-elected to the firm's board. Those two will leave the board along with Director Greg Brown, who resigned following the results of the voting even though he was re-elected. David Sparling, VP of legal and corporate development for the firm, also tendered his resignation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."